2.9(top 6%)
Impact Factor
3.1(top 6%)
extended IF
116(top 3%)
H-Index
1.8K
authors
7.3K
papers
150.1K
citations
7K
citing journals
54.1K
citing authors

Most Cited Articles of Journal of Clinical Pharmacology

TitleYearCitations
Danshen: an overview of its chemistry, pharmacology, pharmacokinetics, and clinical use2005973
A classification of antiarrhythmic actions reassessed after a decade of new drugs1984601
Pharmacokinetics and bioavailability of quercetin glycosides in humans2001423
A mechanistic approach to understanding the factors affecting drug absorption: a review of fundamentals2002392
The Anticholinergic Drug Scale as a measure of drug-related anticholinergic burden: associations with serum anticholinergic activity2006385
Global burden of disease (GBD) for hepatitis C2004375
DHEA and DHEA-S: a review1999370
Multiple drug resistance in cancer revisited: the cancer stem cell hypothesis2005350
Pharmacokinetics and pharmacodynamics of LCZ696, a novel dual-acting angiotensin receptor-neprilysin inhibitor (ARNi)2010337
Clinical safety, tolerability, pharmacokinetics, and pharmacodynamics of the novel factor Xa inhibitor edoxaban in healthy volunteers2010337
Cannabidiol: an overview of some pharmacological aspects2002306
Metabolism and disposition of the thienopyridine antiplatelet drugs ticlopidine, clopidogrel, and prasugrel in humans2010296
Pharmacokinetics and pharmacodynamics of zoledronic acid in cancer patients with bone metastases2002292
Nuclear receptors and the regulation of drug-metabolizing enzymes and drug transporters: implications for interindividual variability in response to drugs2007283
Doxorubicin encapsulated in liposomes containing surface-bound polyethylene glycol: pharmacokinetics, tumor localization, and safety in patients with AIDS-related Kaposi's sarcoma1996280
New era in drug interaction evaluation: US Food and Drug Administration update on CYP enzymes, transporters, and the guidance process2008273
Nuclear factor kappa B: important transcription factor and therapeutic target1998272
Stability and performance of a population pharmacokinetic model1997261
Effects of celecoxib, a novel cyclooxygenase-2 inhibitor, on platelet function in healthy adults: a randomized, controlled trial2000261
Pharmacokinetics and bioavailability of mycophenolate mofetil in healthy subjects after single-dose oral and intravenous administration1996253
Effects of nonsteroidal antiinflammatory drugs on platelet function and systemic hemostasis1995235
Prediction of human pharmacokinetics from preclinical information: comparative accuracy of quantitative prediction approaches2009233
Body weight has limited influence on the safety, tolerability, pharmacokinetics, or pharmacodynamics of rivaroxaban (BAY 59-7939) in healthy subjects2007231
Evidence of plasma CoQ10-lowering effect by HMG-CoA reductase inhibitors: a double-blind, placebo-controlled study1993229
Dose-dependent pharmacokinetics and psychomotor effects of caffeine in humans1997228